BEIJING, July 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) met the primary endpo…
RNS Number : 0058O Bank of Nova Scotia 27 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING…
RNS Number : 0056O Amundi SA 27 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DISCL…
Bagsværd, Denmark, 27 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe…
RNS Number : 0054O Bank of Nova Scotia 27 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING…
RNS Number : 0052O TrinityBridge Limited 27 July 2026 FORM 8.3PUBLIC DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positi…
RNS Number : 0053O Societe Generale SA 27 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING…
RNS Number : 0051O Wellington Management Group LLP 27 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")Public disclosures under Rule 8 of the Code must be mad…
RNS Number : 0035O Societe Generale SA 27 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING…
RNS Number : 0034O Societe Generale SA 27 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING…
RNS Number : 0016O TruFin PLC 27 July 2026 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.LEI: 213800C2QPZFECSRZ96427…
-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model.-Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will be submitted to the U.S. Food and Drug Administration (FDA) v…
RNS Number : 0018O FIL Limited 27 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DIS…
RNS Number : 0017O Frontier Developments PLC 27 July 2026 TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BBT32N39Issuer NameFRONTIER DEVELOPMENTS PLCUK or Non-UK IssuerUK2. Reason for NotificationAn acquisition or disposal of voting rights3. Details of person sub…
RNS Number : 0014O Societe Generale SA 27 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING…
RNS Number : 0012O FIL Limited 27 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DIS…
RNS Number : 0013O Societe Generale SA 27 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING…
Revenue from operations grew 25% year-over-year in Q1 FY 2026-27, with profit after tax rising 8%. The order book reached ₹72,258 crore, and a final dividend of 55% was recommended. No material impact from geopolitical risks identified.Original document: Bharat Electronics Limited [BEL] Interim rep…
RNS Number : 0008O Societe Generale SA 27 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING…
Q1 FY 2027 saw 37.9% YoY revenue growth to INR 859 crore, with solar pump volumes up 57.6%. EBITDA margin held at 9.6% sequentially, while PAT rose 35% to INR 52 crore. Strong order book, capacity expansion, and diversification into rooftop and retail segments support a positive outlook.Based on Sh…
